ST Renfu (600079.SH): Sufentanil Citrate Injection Receives Clinical Trial Approval Notice

Gelonghui, August 10 — ST Renfu (600079.SH) announced that its majority-owned subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (hereinafter referred to as “Yichang Renfu,” in which the company holds an 80% equity interest), recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for sufentanil citrate injection. Sufentanil is a potent opioid analgesic and a selective μ-opioid receptor agonist. Yichang Renfu’s sufentanil citrate injection was initially approved for marketing in 2005 and passed the consistency evaluation of quality and efficacy for generic drugs in 2020, with the approved indication being “for use in endotracheal intubation…”

Gelonghui FinanceAug 10 15:54

Humanwell Healthcare's Unit Gets Registration Certificate for Brexpiprazole Tablets

MT NewswiresAug 7 14:37

ST Renfu (600079.SH) has received acceptance from the Shanghai Stock Exchange for its application to issue A-shares to specific investors.

ST Renfu (600079.SH) announced that on August 3, 2026, the company received a notice from the Shanghai Stock Exchange (the "SSE"), titled "Notice on Acceptance of the Application for Securities Issuance by Renfu Pharmaceutical Group Co., Ltd., a Main Board Listed Company on the Shanghai Stock Exchange." The SSE, in accordance with relevant regulations, reviewed the prospectus and related application documents submitted by the company for securities issuance as a Main Board listed company on the Shanghai Stock Exchange, and determined that the application documents are complete and conform to the required legal form. The SSE has therefore decided to accept the application and proceed with the review in accordance with the law.

Zhitong FinanceAug 4 16:34

Results of the 12th batch of national centralized procurement announced, with leading manufacturers securing major orders.

① All 65 products were successfully procured, with 327 companies and 521 products provisionally selected; ② Competitive dynamics for several high-profile products have been reshaped, with leading enterprises securing a larger share of provisional selections, and procurement rules further optimized; ③ The 'anti-grind' (anti-excessive competition) mechanism is showing initial effectiveness, as centralized procurement shifts from price-driven competition toward comprehensive capability assessment.

cls.cnAug 1 20:00

Express News | ST Renfu: Wholly-owned subsidiary sells 16.34% stake in Lefusi for RMB 1.062 billion

BreakingsJul 28 23:58

Following China Merchants Group's takeover, asset streamlining accelerates; ST Renfu offloads Jissbon for RMB 1.062 billion

① ST Renfu plans to divest its entire 16.34% stake in Lifestyles, the parent company of Jissbon, for RMB 1.062 billion, which is expected to impact the current period’s profit and loss by approximately RMB 500 million. ② Upon completion of the transaction, Wuhan Hairun will become the largest shareholder, as ST Renfu further exits non-core assets and refocuses on its core pharmaceutical business.

cls.cnJul 28 23:17